ArticleScientific reports2018
Genetically engineered two-warhead evasins provide a method to achieve precision targeting of disease-relevant chemokine subsets.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Evasins: Biology and Therapeutic Potential of Broad-Spectrum Chemokine Inhibitors.Basic & clinical pharmacology & toxicology · 2026Review
- Development of chemokine network inhibitors using combinatorial saturation mutagenesis.Communications biology · 2025Article
- Assessing customized multivalent chemokine-binding peptide treatment in a murine model of coxsackievirus B3 myocarditis.Basic research in cardiology · 2025Article
- Ticks' tricks: immunomodulatory effects of ixodid tick saliva at the cutaneous tick-host interface.Frontiers in immunology · 2025Review
- Binding Molecules in Tick Saliva for Targeting Host Cytokines, Chemokines, and Beyond.Biomolecules · 2024Review
- Discovery and pharmacophoric characterization of chemokine network inhibitors using phage-display, saturation mutagenesis and computational modelling.Nature communications · 2023Article
- Engineering broad-spectrum inhibitors of inflammatory chemokines from subclass A3 tick evasins.Nature communications · 2023Article
- Iripin-1, a new anti-inflammatory tick serpin, inhibits leukocyte recruitmentFrontiers in immunology · 2023Article
- Phylogenetic Analysis Indicates That Evasin-Like Proteins of Ixodid Ticks Fall Into Three Distinct Classes.Frontiers in cellular and infection microbiology · 2021Article
- Engineered anti-inflammatory peptides inspired by mapping an evasin-chemokine interaction.The Journal of biological chemistry · 2020Article
- Evasins: Tick Salivary Proteins that Inhibit Mammalian Chemokines.Trends in biochemical sciences · 2020Review
- A knottin scaffold directs the CXC-chemokine-binding specificity of tick evasins.The Journal of biological chemistry · 2019Article
- Chemical Equilibrium at the Tick-Host Feeding Interface:A Critical Examination of Biological Relevance in Hematophagous Behavior.Frontiers in physiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Both CC and CXC-class chemokines drive inflammatory disease. Tick salivary chemokine-binding proteins (CKBPs), or evasins, specifically bind subsets of CC- or CXC-chemokines, and could precisely target disease-relevant chemokines. Here we have used yeast surface display to identify two tick evasins: a CC-CKBP, P1243 from Amblyomma americanum and a CXC-CKBP, P1156 from Ixodes ricinus. P1243 binds 11 CC-chemokines with K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.